Chemence Medical’s Exofin Precision Pen Earns FDA Nod

Adhesive-based medical device maker and distributor Chemence Medical earned U.S. Food and Drug Administration (FDA) clearance for its Exofin Precision Pen for wound closure. The device enables more versatility and exactness in closing wounds while facilitating application of topical skin adhesive.
 
According to the company, Exofin Precision Pen is the only pen-style applicator with an adjustable tip to control adhesive width by supporting three application methods in one device: a micro-bristle brush for wide coverage, inverted brush for narrow lines, and angle precision tip for micro lines.
 
Its ergonomic design features a grooved non-slip surface, pressure-controlled variable adhesive flow rate, see-through activation chamber, and up to 152 percent more usable adhesive than other products, according to the company.
 
It provides a 14-day microbial barrier and allows showering without special coverage or wound dressings.
 
“In listening to feedback from physicians, it became clear every patient is different and every procedure is unique in a variety of ways,” Jeff Roberson, president of Chemence told the press. “Doctors and surgeons emphasized they wanted an adhesive that could be applied with precision, regardless of the wound size or location, even in the most delicate procedures.” “We designed the Exofin Precision Pen to meet these needs by making it natural to hold, incorporating multiple applicators, and allowing doctors to vary the flow of adhesive with a pressure-controlled delivery system and higher viscosity formulation while maintaining the fast dry times of our other Exofin products.”